Successful Treatment of Chronic Hand Eczema with Oral 9-&lt;i&gt;cis&lt;/i&gt;-Retinoic Acid

Bollag, W.; F, Ott

doi:10.1159/000018280

Cited by 57 publications

(50 citation statements)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 All forms of eczema responded and adverse effects were reportedly mild. These encouraging findings lead to further trials of alitretinoin in the treatment of hand eczema.…”

Section: Alitretinoinmentioning

confidence: 99%

“…They have been shown to affect cell proliferation and differentiation, apoptosis, angiogenesis, keratinisation and sebum secretion, and to have immunomodulatory properties. 7 This diversity partly reflects differences in their binding with two subtypes of nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs). The natural ligand for RARs is tretinoin (all-trans retinoic acid); ligand binding to RARs is modulated by RXRs, for which the natural ligand is alitretinoin (9-cis-retinoic acid).…”

Section: Alitretinoinmentioning

confidence: 99%

See 1 more Smart Citation

Alitretinoin (Toctino): new oral retinoid for chronic hand eczema

English¹

2009

Prescriber

View full text Add to dashboard Cite

“…7 All forms of eczema responded and adverse effects were reportedly mild. These encouraging findings lead to further trials of alitretinoin in the treatment of hand eczema.…”

Section: Alitretinoinmentioning

confidence: 99%

Section: Alitretinoinmentioning

confidence: 99%

Alitretinoin (Toctino): new oral retinoid for chronic hand eczema

English¹

2009

Prescriber

View full text Add to dashboard Cite

“…Grupa badana składająca się z 38 pacjentów była leczona alitretynoiną w dawce 20-40 mg przez 1-5 miesięcy. Skuteczność terapii sięgała 89% [25]. Kolejne dwa duże badania randomizowane z zastosowaniem podwójnie ślepej próby przeprowadzili Ruzicka i wsp.…”

Section: Skuteczności Alitretynoinyunclassified

“…Ze wzglę-du na wpływ alitretynoiny na proliferację komórek działa ona potencjalnie teratogennie i dlatego, jak każdy retinoid, jest bezwzględnie przeciwwskazana w ciąży i w okresie karmienia. Zaleca się stosowanie skutecznej antykoncepcji i przeprowadzanie testów ciążowych o odpowiedniej czułości przed leczeniem, w trakcie terapii i miesiąc po zakończeniu leczenia [7,25]. Przed rozpoczęciem terapii, a także w jej trakcie ważne jest monitorowanie stężenia cholesterolu, transaminaz, hormonu tyreotropowego (TSH) oraz morfologii krwi.…”

Section: Skuteczności Alitretynoinyunclassified

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Matejko¹,

Krêcisz²

2016

View full text Add to dashboard Cite

Przegląd Dermatologiczny 2016/5 StreSzczeniePrzewlekły wyprysk kontaktowy rąk to powszechne schorzenie, któ-re wywiera negatywny wpływ na funkcjonowanie i psychikę chorego. Stosowanie dostępnych, tradycyjnych metod leczniczych, takich jak miejscowe glikokortykosteroidy, inhibitory kalcyneuryny, fototerapia, leki immunosupresyjne, jest często niesatysfakcjonujące ze względu na brak zadowalającego rezultatu lub skutki uboczne. Alitretynoina (kwas 9-cis-retinowy) to aktywna substancja z grupy retinoidów zarejestrowana do ogólnoustrojowej terapii przewlekłego wyprysku kontaktowego rąk opornego na leczenie miejscowe. Jest agonistą zarówno receptorów RAR (receptory kwasu retinowego), jak i RXR (receptory X retinoidów) oraz pełni funkcję przeciwzapalną i immunomodulującą, ingerując w reakcję zapalną na różnych jej odcinkach. Dobra tolerancja leku oraz potwierdzona w badaniach klinicznych skuteczność terapeutyczna wskazują, że alitretynoina może być korzystną alternatywą leczniczą dla pacjentów z przewlekłym wypryskiem rąk opornym na inne formy terapii. AbStrActHand eczema is a common skin disorder with significant functional and economic impacts. Conventional therapy options, such as topical corticosteroids, calcineurin inhibitors, phototherapy and systemic immunosuppressants, often give unsatisfactory results, due to lack of efficacy or predominant adverse effects. Alitretinoin (9-cis-retinoic acid) is an active substance from the group of retinoids and is licensed as a systemic drug for chronic and severe hand eczema refractory to topical treatment. It binds with high affinity to both retinoic acid receptor (RAR) and retinoid X receptor (RXR) receptors and presents anti-inflammatory and immunomodulatory activity. Due to its good tolerance and high efficacy, demonstrated in several large clinical studies, alitretinoin may be an option for patients with severe chronic hand eczema refractory to other treatment. kontaktowe zapalenie skóry, wyprysk rąk oporny na leczenie, kwas 9-cis-retinowy, alitretynoina.

show abstract

“…24 Given its effects on cell proliferation, alitretinoin is a potent teratogen and is therefore contraindicated in pregnant women and women who might become pregnant during the course of treatment. 25 Moreover, studies on rat embryos have demonstrated that it can cause deleterious malformations at the second visceral arch. 26 Alitretinoin's effects on cell proliferation have been exploited for beneficial effects as well; a recent study demonstrated its ability to induce apoptosis in breast cancer cells.…”

Section: Alitretinoin Backgroundmentioning

confidence: 99%

Update on the use of alitretinoin in treating chronic hand eczema

Ghasri¹,

Scheinfeld²

2010

CCID

View full text Add to dashboard Cite

Abstract:Chronic hand eczema is a debilitating dermatological condition with significant economic, social, and functional impacts. To date, conventional treatments such as topical corticosteroids, phototherapy, and systemic immunosuppressants have yielded disappointing results, owing to either a lack of efficacy or significant adverse events. Oral alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid with immunomodulatory and antiinflammatory activity that has emerged as a novel treatment for chronic hand eczema. Several large-scale clinical studies have demonstrated oral alitretinoin's high efficacy rate of 28% to 89%, its safe tolerability profile, and its positive impact on quality of life, validating it as a therapeutic option for patients with severe chronic hand eczema refractory to standard treatment. Keywords: hand eczema, alitretinoin, 9-cisretinoic acid Chronic hand eczema BackgroundEczema is the most common dermatological disorder of the hands, with an annual prevalence of up to 12% and 16% in parts of Europe and the United States, respectively. 1,2Hand eczema is characterized by vesicles, papules, erythema, edema, scaling, fissures, and hyperkeratosis, as well as pruritic and painful symptoms.3,4 While there is no specific morphological classification system, clinical subtypes include vesicular, atopic, endogenous, discoid, acral, irritant, pompholyx, and hyperkeratotic eczema. 5Included in the differential diagnosis are irritant contact dermatitis, allergic contact dermatitis, endogenous eczema, psoriasis/pustulosis, fungal infection, keratoderma, lichen planus, and granuloma annulare. Hand eczema has a multi-factorial etiology, involving both endogenous and exogenous factors. 7 The primary endogenous predisposing factor is a history of atopy, which is the underlying etiology in as high as 50% of affected individuals.3 Genetic inheritance also plays a role, as demonstrated by a recent population-based twin cohort study.8 Exogenous factors primarily include exposure to irritants (ie, food, oils, soap, solvents), and contact allergens (ie, nickel, chromate, rubber). Occupational exposure to these causative agents, primarily among dressers, cooks, healthcare workers, for example, are the most common causes of hand eczema. 9 The interrelatedness of these etiologies renders it difficult to isolate and remove the offending agents, and is therefore a factor for development of hand eczema into a chronic, relapsing course.When hand eczema persists for more than 6 months despite therapeutic measures, it is considered to be a chronic form. 6 This variant of hand eczema develops in

show abstract

Successful Treatment of Chronic Hand Eczema with Oral 9-<i>cis</i>-Retinoic Acid

Cited by 57 publications

References 7 publications

Alitretinoin (Toctino): new oral retinoid for chronic hand eczema

Alitretinoin (Toctino): new oral retinoid for chronic hand eczema

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Update on the use of alitretinoin in treating chronic hand eczema

Contact Info

Product

Resources

About